Loading cancer entity…
Loading cancer entity…
Clinical trials
1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06285370 | A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy | completed | Phase 4 | 23 | Kyowa Kirin China Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05160922 | Crizotinib Continuation Clinical Study | active not recruiting | Phase 4 | 27 | PfizerINDUSTRY | 5 | Mar 30, 2026 | clinicaltrials |
| NCT05442554 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma | completed | Phase 4 | 10 | TakedaINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07046182 | Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight | active not recruiting | Phase 4 | 34 | Zhengzhou UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT01804166 | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | completed | Phase 4 | 1 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02323659 | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas | terminated | Phase 4 | 100 | Polish Lymphoma Research GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT04999878 | A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.(RUE-DDGP) | unknown | Phase 4 | 30 | Zhengzhou UniversityOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04490590 | A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma | unknown | Phase 4 | 30 | Mingzhi ZhangOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04040491 | PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | unknown | Phase 4 | 100 | Mingzhi ZhangOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 4 | 59 | Bausch Health Americas, Inc.INDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04038411 | PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma | unknown | Phase 4 | 50 | Mingzhi ZhangOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT03707847 | Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT03558412 | A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma | unknown | Phase 4 | 40 | Mingzhi ZhangOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03226119 | MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study | completed | Phase 4 | 150 | MP Biomedicals, LLCINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT00221039 | Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A | completed | Phase 4 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT03631862 | Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 4 | 100 | Zhengzhou UniversityOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT03071822 | Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas | unknown | Phase 4 | 50 | The University of Hong KongOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT01746992 | CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma | unknown | Phase 4 | 200 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01569724 | Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma(TgBEX) | completed | Phase 4 | 10 | Rennes University HospitalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT03150602 | A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy | unknown | Phase 4 | 22 | Taiwan Mundipharma Pharmaceuticals Ltd.INDUSTRY | 1 | May 12, 2017 | clinicaltrials |
| NCT01625455 | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome | terminated | Phase 4 | 7 | Vanderbilt University Medical CenterOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT02487316 | A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | withdrawn | Phase 4 | 0 | Jun ZhuOTHER | 1 | Dec 30, 2016 | clinicaltrials |
| NCT01664975 | Treatment of Peripheral T-cell Lymphoma | completed | Phase 4 | 100 | Mingzhi ZhangOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT01501136 | Treatment of Natural Killer/T Cell Lymphoma-I/II(CTTNKTL-I/II) | unknown | Phase 4 | 200 | Mingzhi ZhangOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT01501149 | Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ(CTTNKTL-Ⅲ/Ⅳ) | unknown | Phase 4 | 80 | Mingzhi ZhangOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT01418430 | Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) | completed | Phase 4 | — | King's College Hospital NHS TrustOTHER | 1 | Aug 22, 2011 | clinicaltrials |
| NCT00630903 | PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides(MF99) | terminated | Phase 4 | 54 | Madrilenian Group of Cutaneous LymphomasOTHER | 1 | Mar 7, 2008 | clinicaltrials |
| NCT00050999 | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | completed | Phase 4 | 195 | Eisai Inc.INDUSTRY | 10 | Mar 5, 2008 | clinicaltrials |
| NCT00051012 | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients | completed | Phase 4 | 86 | Eisai Inc.INDUSTRY | 9 | Mar 5, 2008 | clinicaltrials |
Data updated 20 days agoSource updated Sep 9, 2026source: clinicaltrials